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Abstract
Objective—To characterize administration of sedatives, analgesics, and paralytics in a large 
cohort of mechanically ventilated, premature infants.
Study design—Retrospective cohort study including all infants <1500 g birth weight and <32 
weeks gestational age mechanically ventilated at 348 Pediatrix Medical Group neonatal intensive 
care units (NICU) from 1997–2012. The primary outcome is the proportion of mechanically 
ventilated days in which infants were administered drugs of interest. Multivariable logistic 
regression was used to evaluate the predictors of administration of drugs of interest.
Results—We identified 85,911 mechanically ventilated infants. Infants received a drug of 
interest (opioids, benzodiazepines, other sedatives, and paralytics) on 433,587/1,305,413 (33%) of 
mechanically ventilated infant-days. The administration of opioids increased during the study 
period from 5% of infant-days in 1997 to 32% in 2012. The administration of benzodiazepines 
increased during the study period from 5% of infant-days in 1997 to 24% in 2012. Use of 
paralytics and other drugs remained ≤1% throughout the study period. Predictors of drug 
administration included younger gestational age, small for gestational age status, male sex, major 
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congenital anomaly, older postnatal age at intubation, exposure to high frequency ventilation, 
exposure to inotropes, more recent year of discharge, and NICU site.
Conclusion—Administration of opioids and benzodiazepines in mechanically ventilated 
premature infants increased over time. Because infant characteristics were unchanged, site-specific 
differences in practice likely explain our observations. Increased administration over time is 
concerning given limited evidence of benefit and potential for harm.
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comfort drugs; ventilated infants
Premature infants admitted to neonatal intensive care units (NICUs) frequently receive 
mechanical ventilation through an endotracheal tube.(1) Mechanical ventilation has been 
associated with pain, distress, and feelings of breathlessness in older children and adults.(2, 
3) To alleviate these discomforts and facilitate gas exchange during mechanical ventilation, 
children and adults routinely receive sedatives and analgesics.(4, 5) However, routine 
administration of analgesics in premature infants receiving mechanical ventilation may be 
associated with harm.(6–11)
Randomized controlled trials of routine morphine administration demonstrate an increased 
incidence of hypotension, drug dependence, air leaks, prolonged duration of mechanical 
ventilation, and prolonged time to full enteral feeds.(6–11) Opioids also are associated with 
apoptosis in the developing brains of animals, and although it is unknown how extensively 
this occurs in humans, concerns about adverse neurocognitive outcomes associated with 
opioid use during infancy exist.(12–17) Based on available evidence, guidelines in 2006 
recommended against routine use of sedatives and analgesics in premature infants receiving 
mechanical ventilation.(18, 19) Guidelines regarding use of paralytics in preterm infants do 
not currently exist. Even though some studies suggested possible benefits in infants with 
ventilator dyssynchrony, routine use of paralytics in preterm infants may be associated with 
sustained paralysis, joint contractures, and hearing loss.(20–23)
The frequency and determinants of sedative and analgesic use in premature infants receiving 
mechanical ventilation are not well described. Information regarding determinants of 
sedative and analgesic use in this population will help identify infants at risk for associated 
adverse neurocognitive outcomes, and will allow more efficient design of future trials 
investigating the risks and benefits of sedative and analgesic administration. Here, we seek 
to characterize the use of sedatives, analgesics, and paralytics over time in a large cohort of 
mechanically-ventilated premature infants, and to identify factors associated with use.
METHODS
We obtained data from the Pediatrix Medical Group Data Warehouse, which prospectively 
captures information from an electronic medical record of daily progress notes and other 
documentation prepared by clinicians involved in the care of infants. Information is 
collected regarding maternal history and demographics, drugs, laboratory results, culture 
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results, mechanical ventilation and respiratory support, and diagnoses. Details of 
administered drug dose were not recorded during this study period.
We identified all infants <1500 g birth weight and <32 weeks gestational age (GA) who 
received ≥1 day of mechanical ventilation (high frequency or conventional) in the first 120 
days of life during their initial admission to one of 348 NICUs from 1997 to 2012. We 
followed infants during mechanically-ventilated days, excluding days of a major surgical 
intervention and 6 days following the surgical intervention, from NICU admission until one 
of the following events occurred: death, discharge, or day 120 of admission. We evaluated 
use of sedatives, analgesics, and paralytics measured in infant-days of administration of drug 
during the study period.
We included the following drugs of interest: opioids (fentanyl, morphine, meperidine, 
methadone), benzodiazepines (midazolam, diazepam, clonazepam, lorazepam), paralytics 
(atracurium, mivacurium, pancuronium, rocuronium, vecuronium), and “other” drugs 
(chloral hydrate, dexmedetomidine, ketamine, clonidine). We measured drug use as the 
number of mechanically ventilated infant-days of administration for each drug of interest.
We defined the duration of mechanical ventilation as the total number of days of mechanical 
ventilation during the hospitalization of each infant, excluding the day of major surgery and 
6 days thereafter. We defined surgical intervention as any surgical or catheter-based 
intervention (ie, cardiac catheterization) documented in the chart for which general 
anesthesia was likely. An infant was considered to have a major congenital anomaly if an 
anomaly presenting at birth had one or more of the following characteristics: (1) lethal; (2) 
life-shortening; (3) life threatening; (4) requiring major surgery; or (5) significantly affecting 
the infant’s quality of life. We grouped sites into quartiles of average annual site volume of 
mechanically-ventilated infants during the study period.
Statistical analyses
The primary unit of observation for this study was an infant-day of mechanical ventilation. 
We used standard summary statistics, including counts, percentages, medians, and 25th and 
75th percentiles to describe the study variables. We compared the distribution of infants with 
any drug use across infant characteristics using Wilcoxon rank-sum tests. We evaluated 
trends over time using the Cochran-Armitage test for trend. To evaluate the independent 
associations between infant characteristics and daily exposure to sedatives, analgesics, or 
paralytics of interest, we used multivariable logistic regression with a robust variance 
estimator to account for the clustered nature of the data by infant. The final multivariable 
model included the following predictors: GA (categorical), small for GA status (SGA, 
binary), postnatal age at the time of intubation (categorical), race (categorical), sex (binary), 
exposure to inotropic support (binary), exposure to high frequency ventilation (binary), 
discharge year (categorical), and a binary indicator variable for each site. To investigate the 
potential effect on our results of outliers in mechanical ventilation duration we conducted a 
sensitivity analysis limited to the first 7 days of mechanical ventilation for each infant.
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To characterize differences in drug administration by site, we used the final model without 
the indicator for site to calculate predicted probability of daily drug administration for each 
site.
We used STATA 13.1 (College Station, TX) to perform all statistical analyses. A two-sided p 
<0.05 was considered statistically significant for all tests. The study was approved by the 
Duke University Institutional Review Board without the need for written informed consent 
because the data were collected without identifiers.
RESULTS
We identified 85,911 infants who received mechanical ventilation for a total of 1,305,413 
days at 329 sites. The median GA and postnatal age at initial intubation were 27 weeks 
(interquartile range; 25, 29), and 0 days (0, 0), respectively. Infants were ventilated for a 
median of 6 days (2, 22). 31,078 (36%) infants received high frequency ventilation on 
297,751 (23%) days (Table I).
Over time, the median birth weight among infants in our cohort decreased, the median GA 
remained stable, and the proportion of infants born with a major congenital anomaly 
increased (957 g in 1997 and 890 g in 2012, p=0.001; 27 weeks in 1997 and 2012; and 6% 
in 1997 and 8% of infants in 2012, p=0.027). After 1998, the proportion of infants who 
received high frequency ventilation declined (38% in 1999 and 36% in 2012, p=0.003), as 
did the proportion receiving inotropes during ventilation (37% in 1999 and 33% in 2012, 
p=0.008).
Among infants in our cohort, 32,058 (37%) received ≥1 drug of interest during 433,587 
(33%) ventilated days. Fentanyl, midazolam, and morphine were the most frequently 
administered drugs of interest: 215,663 (17%), 180,791 (14%) and 112,612 (9%) ventilated 
days. Chloral hydrate was the most frequently administered “other” drug, on 7410 (<1%) 
ventilated days, and vecuronium was the most frequently administered paralytic, on 9312 
(<1%) days. Administration of 2 or 3 drugs of interest occurred on 175,437 (13%) and 
16,121 (1%) days, and 4, 5, or 6 drugs of interest were administered on 1693, 126, and 22 
(all <1%) days, respectively. Infants who received a drug of interest were less mature and of 
lower birth weight compared with those who never received any drug [median of 26 weeks 
(25, 28) and 27 weeks (26, 29), p<0.001; 830 g (665, 1063) and 990 g (771, 1213), 
p<0.001].
Providers typically administered opioids and benzodiazepines shortly after initiation of 
mechanical ventilation [median 1 day (0, 6) and 0 days (0, 7)], but administered paralytics 
and “other” sedatives later in the ventilation course [median 8 days (1, 20) and 38 days (24, 
65)]. Infants exposed to a drug of interest during the course of mechanical ventilation were 
exposed for a median of 6 days (2, 19). Median duration of exposure to opioids, 
benzodiazepines, and paralytics were 7 (2, 20), 9 (3, 25), and 12 (4, 30) days, respectively. 
Although exposure to “other” sedatives was relatively rare (<1% of days), median duration 
of exposure to such sedatives was the longest at 28 days (12, 45). Overall, 8% of infants 
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were exposed to drugs of interest for up to 25% of their ventilated days, and 17% were 
exposed for >75% of their ventilated-days.
On multivariable analysis, the following factors were associated with higher prevalence of 
sedative, analgesic, or paralytic administration on an infant-day: younger GA, SGA status, 
male sex, major congenital anomaly, older postnatal age at intubation, exposure to high 
frequency ventilation, and exposure to inotropes (Table II). When we limited our analysis to 
include only the first 7 days of mechanical ventilation for each infant in our cohort, GA, 
SGA status, and male sex were no longer significant predictors of administration of drugs of 
interest.
Administration of drugs of interest during mechanical ventilation varied substantially across 
sites [median proportion of days: 14% (2, 34) (Figure 1). Compared with lower volume 
centers, higher volume centers more frequently administered drugs of interest [median 
proportion of days: 18% in the first quartile of centers (≤4 infants per year) and 35% in the 
fourth quartile of centers (≥33 infants), p<0.001]. Among the 100 sites with the highest 
percent infant-days of administration of any of the drugs of interest during mechanically-
ventilated infant days (minimum 0.5% of mechanically-ventilated infant days), 
administration of any drug of interest, benzodiazepines, or opioids occurred on 0.7–89%, 
0.7–82%, and 0.7–78% of days, respectively. In Figure 1, such variability in drug 
administration among these 100 sites is demonstrated for any drug of interest, 
benzodiazepines, and opioids. As also shown in Figure 1 by the overlay of predicted 
probabilities of drug administration for each site, significant variability remained even 
among sites with similar predicted probabilities of drug administration after adjusting for 
infant characteristics at each site.
Administration of opioids during mechanical ventilation increased during the study period 
(678/14,800 days (5%) in 1997 to 29,426/91,418 (32%) in 2012, p <0.001) (Figure 2). 
Administration of benzodiazepines also initially increased (696/14,800 (5%) in 1997 to 
28,891/102,583 (28%) in 2009 (p < 0.001)), but has since slightly decreased to 
22,397/91,418 (24%) in 2012 (p< 0.001). Paralytic and “other” sedative administration 
remained stable throughout the study period with exposure to drugs in both categories 
remaining ≤1% of ventilator days.
DISCUSSION
We conducted a large retrospective cohort study to date evaluating the administration of 
sedatives, analgesics, and paralytics to premature infants receiving mechanical ventilation. 
We found that administration of opioids and benzodiazepines increased over time and varied 
significantly across sites. Our adjusted analysis indicated that patient characteristics, 
including surrogates of illness severity (i.e., the presence of a major congenital anomaly, and 
inotropic or high frequency ventilator support), GA, and postnatal age at intubation were 
independently associated with receipt of drugs of interest. Most importantly however, we 
found that site of hospitalization was an independent predictor of drug administration even 
when the probability of daily drug administration was adjusted for characteristics of infants 
at the site (C-statistic for model with infant characteristics alone and infant characteristics 
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with site indicator variable, 0.62 and 0.80). This finding suggests that site specific factors, 
rather than infant risk factors alone, are associated with sedative and analgesic 
administration in this population, and presents an opportunity for quality improvement 
initiatives aimed at reducing exposure to potentially harmful drugs in premature infants.
The association between infant characteristics and sedative and analgesic administration has 
been previously demonstrated, and may have physiologic basis. (24–26) Administration of 
opioids and benzodiazepines may reduce infant-ventilator dyssynchrony and improve gas 
exchange in critically ill infants, particularly those supported with high frequency 
ventilation.(27–30) Further, compared with younger infants, older infants have increased 
body mass that may allow increased ability to move and display distress during mechanical 
ventilation. (24, 31)
Opioids and benzodiazepines may also decrease a patient’s stress response and metabolic 
demand.(5, 32, 33) In critically ill infants at high risk of mortality, administration of opioids 
and benzodiazepines may decrease oxygen consumption, avoid oxygen debt and associated 
acidosis, and decrease mortality.(5, 34, 35) Our study findings support this hypothesis by 
demonstrating that presence of a major congenital anomaly, high-frequency ventilation use, 
and exposure to inotropes were all associated with increased odds of drug exposure in an 
adjusted analysis. Unlike infant characteristics such as GA, SGA, and gender, which were 
not statistically significant in our analysis limited to the first 7 days, markers of illness 
severity are important contributors to the decisions to initiate and continue administration of 
drugs of interest in a particular patient.
If severity of illness was responsible for the increase in opioid and benzodiazepine 
administration over time, as suggested by minimal increase in the C-statistic from 0.62 to 
0.65 when discharge year was added to infant characteristics in our model, we might expect 
increases in administration of other drugs given to infants with suspected or confirmed 
severe illness. In fact, the observed increases in opioid and benzodiazepine administration 
occurred in a cohort of infants in which administration of the example antibiotic, ampicillin, 
and inotropes decreased slightly over the study period (8% in 1997 and 5% in 2012, 
p<0.001; 3% in 1997 and 2% in 2012, p=0.046) (Figure 2).(36) This finding supports the 
hypothesis that severity of illness alone does not account for the increasing administration of 
opioids and benzodiazepines to mechanically-ventilated premature infants over the study 
period.
Site-level factors including training, institutional policies on assessment and management of 
pain and agitation, or individual patient encounters often influence provider decision making 
and practice, and likely explain the increasing administration of opioids and benzodiazepines 
to mechanically-ventilated, premature infants.(37, 38) In 2001, the Joint Commission 
established standards regarding the assessment and management of pain in patients, and a 
consensus statement recommended routine treatment of pain, including use of continuous 
opioid infusion, in mechanically-ventilated infants of any gestational age.(39–41) Such 
emphasis on pain management in combination with the increased availability of validated 
pain assessment scales in neonates (>25 available scales) likely influenced the increased 
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administration of sedatives and analgesics over time, but sites appear to have adopted 
recommendations to varying degrees.(42–44)
In our study, administration of opioids and benzodiazepines varied widely across the 100 
sites with the highest percent infant-days of administration, and we identified this variation 
even among sites with similar predicted administration of drugs of interest based on infant 
characteristics. Although not applicable to the majority of sites with limited drug 
administration, site-specific quality improvement initiatives may help decrease practice 
variability across NICUs with higher drug utilization.(45) This approach has been 
successfully employed by the Pediatrix Medical Group to limit exposure to histamine-2 
receptor blockers and broad spectrum antibiotics.(46–48) Our study findings strongly 
support the implementation of a similar initiative for opioids and benzodiazepines, which 
may lead to improved short- and long-term outcomes of premature infants requiring 
mechanical ventilation.
The strengths of our study include the use of a multicenter, electronic health record-derived 
database to conduct the largest pharmacoepidemiologic study of sedative, analgesic, and 
paralytics in mechanically-ventilated, premature infants to date. Our access to detailed 
hospital records allowed us to identify several infant characteristics associated with drug 
exposure, and the longevity of the database provided us with an opportunity to demonstrate 
clear trends over time. Finally, the multi-institutional nature of the database, comprised of 
community and academic center-based NICUs that represent almost 25% of all NICU 
admissions in the United States over the study period, was essential to describe site 
variability and identify potential targets for quality improvement initiatives.(47)
Despite the strengths of our data source, some limitations exist. Although an electronic 
health record-derived database is representative of daily clinical practice, it has not 
undergone the scrutiny of a clinical trial database. A more detailed description of infant 
severity of illness, including mechanical ventilator measurements and markers of adequacy 
of gas exchange was not available. Instead, we reported surrogates of severity of illness 
previously used in Pediatrix data analyses.(24) Even though we were able to identify site 
variability in drug exposure, we lacked details about the characteristics of individual sites 
(including academic vs. private setting, number of providers, and site level) to completely 
describe sites with high and low drug use. Finally, we lacked information about drug dosing, 
exposure, or any other measures of drug tolerance to evaluate their associations with harm.
In summary, we found an increasing administration of potentially harmful sedatives and 
analgesics to mechanically ventilated premature infants, and this increase was not fully 
explained by infant severity of illness. Instead, large variability across NICUs suggests that 
site-specific quality improvement initiatives may successfully limit administration of these 
potentially harmful drugs, improving outcomes in this fragile population.
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Figure 1. 
Predicted probability of drug administration by site, and administration of (a) any sedative, 
analgesic, or paralytic, (b) benzodiazepines, and (c) opioids among the 100 sites with most 
frequent drug administration [Footnote: dBased on characteristics of infants cared for at each 
site].
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Figure 2. 
Opioid and benzodiazepine administration compared with ampicillin and inotrope 
administration over time.
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Table 1
Demographics of mechanically ventilated premature infants by exposure to any sedatives, analgesics or 
paralytics from 1997 to 2012.
Any exposure
N=32,058 (%)
No exposure
N= 53,853 (%)
Male 17,706 (55) 28,224 (52)
SGA 5550 (17) 7526 (14)
GA (weeks)
  ≤25 12,895 (40) 12,345 (23)
  26–28 13,150 (41) 23,758 (44)
  29–32 6013 (19) 17,750 (33)
PNA (days)
  ≤ 1 28,749 (90) 49,516 (92)
  2–7 1283 (4) 1917 (4)
  8–28 1253 (4) 1718 (3)
  >28 773 (2) 702 (1)
Race/Ethnicity
  White 14,898 (48) 23,967 (46)
  Black 8184 (26) 14,377 (28)
  Hispanic 6476 (21) 10,893 (21)
  Other 1562 (5) 2660 (5)
Major congenital anomaly 3355 (10) 3275 (6)
High frequency ventilation 18,281 (57) 12,797 (24)
Inotropic support 18,222 (57) 12,514 (23)
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Table 2
Adjusted odds ratios (95% confidence intervals)* of infant characteristics for any sedative, analgesic, or 
paralytic administration to premature infants receiving mechanical ventilation from 1997 to 2012
Adjusted OR (95% CI)
Male 1.06 (1.02, 1.10)
SGA 1.11 (1.05, 1.17)
GA (weeks)
  ≤ 25 REF
  26–28 0.85 (0.81, 0.89)
  29–≤32 0.82 (0.77, 0.88)
PNA (days)
  ≤ 2 REF
  3–7 1.07 (0.96, 1.19)
  8–28 1.07 (0.96, 1.19)
  > 28 1.76 (1.47, 2.09)
Race/Ethnicity
  White REF
  Black 0.99 (0.94, 1.04)
  Hispanic 0.96 (0.90, 1.02)
  Other 0.88 (0.81, 0.97)
Major congenital anomaly 1.31 (1.22, 1.40)
High frequency ventilation 2.58 (2.49, 2.67)
Inotropic support 1.74 (1.68, 1.81)
*
also adjusted for site and year of discharge
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